California Public Employees Retirement System Has $4.12 Million Holdings in Horizon Pharma PLC (NASDAQ:HZNP)

California Public Employees Retirement System increased its holdings in shares of Horizon Pharma PLC (NASDAQ:HZNP) by 3.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 325,085 shares of the biopharmaceutical company’s stock after acquiring an additional 10,585 shares during the period. California Public Employees Retirement System owned about 0.20% of Horizon Pharma worth $4,122,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of HZNP. BlackRock Inc. raised its stake in shares of Horizon Pharma by 1.8% in the second quarter. BlackRock Inc. now owns 13,500,226 shares of the biopharmaceutical company’s stock worth $160,247,000 after acquiring an additional 239,014 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Horizon Pharma by 1.8% during the second quarter. Vanguard Group Inc. now owns 12,982,718 shares of the biopharmaceutical company’s stock worth $154,105,000 after buying an additional 233,443 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Horizon Pharma by 18.6% during the third quarter. Dimensional Fund Advisors LP now owns 7,433,330 shares of the biopharmaceutical company’s stock worth $94,254,000 after buying an additional 1,167,722 shares during the last quarter. Paulson & CO. Inc. bought a new stake in shares of Horizon Pharma during the second quarter worth approximately $58,584,000. Finally, State Street Corp raised its stake in shares of Horizon Pharma by 12.0% during the second quarter. State Street Corp now owns 4,906,307 shares of the biopharmaceutical company’s stock worth $58,241,000 after buying an additional 524,187 shares during the last quarter. Institutional investors and hedge funds own 86.58% of the company’s stock.

A number of research analysts recently issued reports on HZNP shares. BidaskClub cut shares of Horizon Pharma from a “buy” rating to a “hold” rating in a report on Tuesday. Mizuho upgraded shares of Horizon Pharma from a “neutral” rating to a “buy” rating and upped their price target for the company from $12.00 to $18.00 in a report on Friday, January 12th. Cantor Fitzgerald set a $17.00 price target on shares of Horizon Pharma and gave the company a “buy” rating in a report on Monday, January 8th. ValuEngine lowered shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Finally, UBS Group set a $20.00 price target on shares of Horizon Pharma and gave the stock a “buy” rating in a research report on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $19.25.

Horizon Pharma PLC (NASDAQ:HZNP) opened at $14.99 on Thursday. The company has a market cap of $2,396.01, a PE ratio of -4.91, a P/E/G ratio of 0.68 and a beta of 1.30. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.64 and a quick ratio of 1.52. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $17.69.

Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.04. Horizon Pharma had a negative net margin of 45.28% and a positive return on equity of 20.22%. The firm had revenue of $271.60 million for the quarter, compared to the consensus estimate of $259.74 million. During the same period in the prior year, the company posted $0.70 earnings per share. The business’s revenue for the quarter was up 30.1% on a year-over-year basis. research analysts anticipate that Horizon Pharma PLC will post 0.72 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “California Public Employees Retirement System Has $4.12 Million Holdings in Horizon Pharma PLC (NASDAQ:HZNP)” was first reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/california-public-employees-retirement-system-buys-10585-shares-of-horizon-pharma-plc-hznp/1824513.html.

Horizon Pharma Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.